CRA was retained by counsel for the Plaintiff in a patent infringement suit involving an antiemetic agent for the prevention of chemotherapy-induced nausea and vomiting as well as acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy. CRA prepared an expert report and provided trial testimony demonstrating commercial success, ultimately leading to a successful outcome and a ruling that that the subject patents were not invalid.
Who bore the tariff burden? Economics of IEEPA refund disputes
The refund question sits at the intersection of customs procedure, administrative law, but also economics, and resolution will likely vary significantly across...